Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Maintenance therapy in urothelial carcinoma

Srikala S. Sridhar, MD, MSc, FRCPC, Princess Margaret Hospital, Toronto, Canada, discusses the future of maintenance therapy in urothelial carcinoma (UC). There is a growing trend of utilizing maintenance therapy, as it can maintain the positive effects of prior chemotherapy. Using novel agents and immunotherapies such as pembrolizumab as maintenance therapy has shown to have positive benefits in patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Srikala S. Sridhar, MD, MSc, FRCPC has received consultancy/advisory fees from Merck, Pfizer, Roche, BMS, Bayer, Astra Zeneca, Astellas, Janssen, Seattle Genetics, and Immunomedex.